Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of ethinyl-estradiol?

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 6, 2013, Pages 1059-1068

  Bird, S T ^a,b   Delaney, J A C ^c   Etminan, M ^d   Brophy, J M ^e   Hartzema, A G ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Comparative study; Contraception; Drospirenone; Levonorgestrel; Venous thromboembolism

Indexed keywords

DROSPIRENONE; ETHINYLESTRADIOL; LEVONORGESTREL;

ADULT; ANTICOAGULATION; ARTICLE; ATTRIBUTABLE RISK; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; FEMALE; HAZARD RATIO; HUMAN; ICD-9-CM; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

COMPARATIVE STUDY; CONTRACEPTION; DROSPIRENONE; LEVONORGESTREL; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; ANDROSTENES; COHORT STUDIES; CONTRACEPTIVES, ORAL; DATABASES, FACTUAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; TIME FACTORS; UNITED STATES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84883815843     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12224     Document Type: Article

References (35)

1. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142, 475 women-years of observation. Contraception 2007; 75: 344-54.
2. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinyestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110: 587-93.
3. van Hylckama V, Helmerhorst FM, Vanderbroucke JP, Dogen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA study. BMJ 2009; 339. doi:10.1136/bmj.b2921.
4. Lidegaard Ø, LØkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339. doi:1136/bmj.b2890.
5. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342. doi:10.1136/bmj.d2139.
6. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using united States claims data. BMJ 2011; 342. doi:10.1136/bmj.d2151.
7. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study [published online ahead of print November 7, 2011]. CMAJ 2011; 183: E1319-25.
8. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, LØkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001-9. BMJ 2011; 343. doi:10.1136/bmj.d6423.
9. Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP Jr, Cooper WO. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013; 87: 93-100.
10. Yaz. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc.; 2010.
11. University of Arkansas for Medical Sciences. LifeLink health plan claims database: overview and study design issues [homepage on the internet]. c2010 [updated 2010; cited 2013 April 2]. Available from http://www.uams.edu/TRI/hsrcore/Lifelink_Health_Plan_Claims_Data_Design Issues_wcost_April2010[1].pdf. Accessed 23 April 2013.
12. Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002; 3: 4.
13. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164: 1965-76.
14. Kluft C, Endrikat J, Mulder SM, Gerlinger C, Heithecker R. A prospective study on the hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 2006; 73: 336-43.
15. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The transnational research group on oral contraceptives and the health of young women. Contraception 1996; 54: 5-13.
16. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contracepties and the risk of venous thromboembolism. Contraception 1997; 56: 141-6.
17. Lewis MA. Advanced pharmacoepidemiologic reasoning: the story of second- and third- generation oral contraceptives: the story of the transnational study on oral contraceptives and the health of young women. In: Hartzema AG, Tilson HH, Chan KA, eds. Pharmacoepidemiology and Therapeutic Risk Management. Cincinnati, OH: Harvey Whitney Books, 2008: 751-88.
18. Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010; 82: 139-46.
19. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 2007; 12: 30-5.
20. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006; 85: 436-40.
21. Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Saf 2008; 17: 297-305.
22. Dinger J, Assmann A, Moehner S. Oral contraceptives and the risk of VTE: reanalysis of the EURAS/LASS Study [abstract]. Pharmacoepidemiol Drug Saf 2011; 20: S74.
23. Food and Drug Administration. Drospirenone-containing combination oral contraceptives briefing document [homepage on the internet]. C2011. [updated 2011 Dec 7; cited 2013 April 2]. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM282464.pdf. Accessed 23 April 2013.
24. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995; 761: 311-35.
25. Oelkers W, Foidard JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816-21.
26. Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care 2002; 7(Suppl 3): 19-26.
27. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotension-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204-13.
28. Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet 2009; 280: 255-61.
29. Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag 2008; 4: 487-92.
30. Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012; 27: 14-24.
31. Bird ST, Hartzema AG, Etminan M, Brophy JM, Delaney JA. Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. Gynecol Endocrinol 2013; 29: 365-9.
32. Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. The association between drospirenone and hyperkalemia: a comparative-safety study. BMC Clin Pharmacol 2011; 11: 23.
33. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 2013; 185: E115-20.
34. Ohoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008 Am J Obstet Gynecol 2012; 207: 377.
35. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2004; 20: 2698-704.